PET/MR scans for newly diagnosed NK/T-cell lymphoma staging
Part of Cancer clinical trials.
This trial studies whether special imaging with PET/MR can help stage (find the extent of) and evaluate treatment effectiveness in people newly diagnosed with NK/T-cell lymphoma. It may help doctors choose the right treatment plan and track how well therapy is working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of NK/T-cell lymphoma based on the WHO 2016 criteria
- You are between 14 and 70 years old
- You have not had any prior treatment for NK/T-cell lymphoma
- You can take part in study procedures and follow the research plan (and give written consent)
- Your overall health function is good enough (ECOG 0 to 2) and you’re expected to live at least 6 months
- You can safely have PET/MR scanning (no major scan safety issues like certain implants)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special PET scan to see how well treatment works for T-NK cell lymphoma. The scan looks for a protein called granzyme B, which may help predict how the disease will respond and what the outlook might be.
This trial uses PET scans and EBV DNA levels to personalize treatment for patients with early-stage nasal NK/T cell lymphoma. It aims to reduce side effects by adjusting therapy based on how well the cancer responds.
This study uses artificial intelligence to analyze PET/CT scans of people with T-NK cell lymphoma. The goal is to see if the AI can help doctors better diagnose this rare cancer, predict how well treatment will work, and forecast long-term outcomes.
This trial looks at whether PET/CT scans can better predict outcomes in people with fast-growing lymphoma. If you are newly diagnosed and receiving standard treatment, the study may help refine how response is evaluated.
This study uses a special PET/MR scan with a tracer called 68Ga-Pentixafor to see if it can better find lymphoma and multiple myeloma spots in the body. It may help doctors get clearer pictures than standard scans.
This study tests a new type of imaging scan (PET/CT or PET/MR) that uses a radioactive tracer to help doctors better detect and diagnose various cancers. The scan targets a specific protein found in tumors, which may help identify cancer more accurately than standard imaging.
Hear when a new NK T-Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.